Freshfields Bruckhaus Deringer LLP (‘Freshfields’) has advised pharmaceutical company STADA  Arzneimittel AG (‘STADA’) on its structured bidding process and subsequent public tender offer by private equity houses Bain Capital and Cinven. Under the terms of the offer, Bain Capital and Cinven would pay €65.28 a share, and investors would receive a dividend of €0.72 a share. The offer puts STADA's equity value at approximately €4.1bn and the company's overall value at approximately €5.32bn.

The offer represents a 49 per cent premium to the share price on 9 December 2016, which was the price reached before specific rumours of a public tender offer surfaced. The offer was regarded as in the best interest of both the shareholders and stakeholders of STADA and an investor agreement was signed on the 10 April 2017. In the agreement, Bain Capital and Cinven have committed themselves to protection provisions for employees, production sites and overall corporate strategy.

The Freshfields team was led by partner Christoph Seibt.